Pitch Introduction
The Quitci Shark Tank India pitch brought a high-stakes medical and psychological discussion to the tank, focusing on one of India’s most persistent public health challenges: smoking addiction. Founders Jeevan and Dr. Vinod Prakash from Kolar, Karnataka, entered the tank seeking ₹50 Lakhs for 2% equity, valuing their startup at ₹25 Crores. With an MBBS doctor at the helm, the brand promised a science-backed, nicotine-free way to quit smoking by addressing both physical cravings and the psychological triggers associated with the habit.
The founders highlighted a common struggle for smokers: while patches and gums handle nicotine withdrawal, they fail to address the hand-to-mouth ritual and daily triggers like stress or social gatherings. Quitci’s solution involved a specialized breathing device called Flow and a range of functional gummies. However, the pitch quickly turned into a rigorous debate when Namita Thapar questioned the clinical evidence and bioavailability of their ingredients, leading to one of the most intense medical scrutinies of the season.
Business Overview
Quitci operates as a comprehensive ecosystem designed to guide smokers through the difficult journey of quitting. Unlike traditional Nicotine Replacement Therapy (NRT) which simply replaces one form of nicotine with another, Quitci focuses on a nicotine-free and smoke-free approach. The business model is structured into three distinct phases: behavioral therapy, physical products for habit replacement, and health recovery supplements.
The brand targets the estimated 267 million tobacco users in India, specifically those who have tried and failed with traditional methods. By manufacturing in India and utilizing D2C channels, the company has managed to serve over 5,000 customers since its launch in late 2023. Their mission is to help 1 Lakh smokers quit within the next year by scaling their production and refining their digital therapy programs.
Product Details
The flagship product is the Flow Flavored Breathing Device. This is a non-electronic, non-vape inhaler that uses flavored organic cores to provide a sensory experience similar to smoking without any harmful combustion or nicotine. It is designed to satisfy the oral fixation and deep breathing triggers that smokers crave during high-stress moments. The device is paired with Zero Craving Gummies, which contain a blend of melatonin, magnesium, theanine, and passion flower to manage withdrawal symptoms and mood swings.
Additionally, they offer DrinkMyGummies, a supplement designed to combat the secondary effects of smoking, such as damage to hair, skin, and nails. The founders emphasize that their products are entirely natural and intended to transition a smoker into a ‘non-smoker’ rather than a long-term user of quitting aids. The Flow 1.2 version was launched in May 2024, marking a significant evolution in their product lineup.
Market Position
Quitci positions itself as a lifestyle-first health intervention. While pharmaceutical giants dominate the NRT space with products like Nicorette, Quitci differentiates itself by being ‘cool’ and non-medicinal in its aesthetic. They leverage the psychological aspect of habit-breaking, which is often neglected by pure medical solutions. Their unique selling proposition (USP) lies in the Flow device, which provides the missing physical sensation that often leads to relapse.
| Business Detail | Information |
|---|---|
| Company Name | Quitci |
| Founder | Jeevan and Dr. Vinod Prakash |
| Product Type | Smoking Cessation Aids |
| Price Range | ₹499 – ₹1,999 |
| Primary Channel | D2C / Website |
| Headquarters | Kolar, Karnataka |
About Founder’s
The story of Quitci is rooted in a long-standing friendship between Jeevan and Dr. Vinod Prakash. They met during their Pre-University (PU) college days and remained close throughout their professional journeys. Dr. Vinod Prakash pursued an MBBS degree, driven by a passion for understanding the human body, but his entrepreneurial spirit led him away from clinical practice toward building businesses.
Before Quitci, Dr. Vinod founded TMC (The Motorist Company), which focused on premium motorcycle accessories and aimed to develop air-bag vests for Indian riders. When that venture faced hurdles, he pivoted to solving the addiction crisis he saw among his peers. Jeevan, with a background in tourism, joined him to handle operations and marketing, bringing a consumer-centric perspective to the medical expertise of Dr. Vinod.
- Dr. Vinod Prakash: MBBS graduate who turned to entrepreneurship during his medical studies.
- Jeevan: Logistics and operations expert with a Bachelor’s in Tourism.
- The TMC Pivot: The founders previously worked on safety gear before identifying the massive gap in the smoking cessation market.
- Rooted in Kolar: The business operates out of Karnataka, bringing a Tier-2 city success story to the national stage.
Shark’s and Founder’s QnA
What is Flow? I didn’t quite understand the mechanism.
Flow is a flared breathing device. It mimics the feeling of smoking without any nicotine, smoke, or burning of any substance. It is not a vape and has no electronic components. You just take a slow drag, and it infuses flavor bursts. It is designed for smokers to handle the oral fixation triggers.
Dr. Vinod, you are an MBBS doctor. Why did you not pursue medicine?
I had a passion to learn about the human body, which is why I did MBBS. But I started my first company, TMC, while I was still in college. I’ve always wanted to build solutions that impact masses through business.
What was the first phase of the business?
Phase one started in November 2023. It was about cognitive behavior therapy (CBT) programs. I used to provide live and recorded sessions to help people understand the psychology of their addiction before we ever introduced physical products.
Namita, you seem skeptical about the ingredients. Why?
Dr. Vinod, I think you are misleading people. You have put 1mg of melatonin, magnesium, and theanine. Everyone uses these for mood, but do you have any evidence gathering? What is the bioavailability? A study for everything exists, but where is your specific clinical evidence that this stops cravings?
How long has the product been in the market?
The gummies were launched only one month ago. We are planning to start clinical studies soon. We’ve currently served 5,000 smokers through our total ecosystem.
Is this just a placebo effect you are selling?
We address the daily triggers. When a smoker has tea or meets friends, they usually reach for a cigarette. Using Flow at that time replaces the habit. It’s about breaking the loop while the gummies help with the internal chemical balance.
Key Stats & Financials
Quitci showcased impressive early traction for a company that only began its product phase in mid-2024. At the time of the pitch, the brand was generating ₹33 Lakhs in monthly sales, placing them on an annual run rate of nearly ₹4 Crores. Their yearly revenue for the previous period was stated at ₹1.1 Crores, reflecting the rapid growth after launching their physical devices.
Revenue and Profitability
- Yearly Revenue: ₹1.1 Crores
- Monthly Sales: ₹33 Lakhs
- Ask: ₹50 Lakhs for 2% Equity
- Valuation: ₹25 Crores
- Customer Base: 5,000+ smokers served
Financial Breakdown
| Metric | Amount / Value |
|---|---|
| Yearly Revenue (FY24) | ₹1.1 Crores |
| Current Monthly Revenue | ₹33 Lakhs |
| Requested Investment | ₹50 Lakhs |
| Equity Offered | 2% |
| Target Customers (Year 1) | 1 Lakh |
| Burn Rate | Low (Bootstrapped) |
Business Potential and TAM
The smoking cessation market in India is a sleeping giant. According to the Global Adult Tobacco Survey (GATS), India is home to the second-largest number of tobacco users in the world. The overall market for smoking cessation products, including NRT and behavioral therapy, is projected to grow as health consciousness rises and government regulations on public smoking tighten. Globally, this market is valued at over $25 Billion, and India’s share is expanding rapidly as disposable income increases in Tier-1 and Tier-2 cities.
Market Size Analysis
With 267 million tobacco users, the total addressable market (TAM) for Quitci is massive. Even if the brand captures just 0.1% of this population, they would have 2.6 Lakh customers. The current market is dominated by pharmaceutical gums and patches which often have a high failure rate because they don’t address the psychological hand-to-mouth habit. This creates a specific ‘Habit Replacement’ sub-sector worth hundreds of crores that Quitci is currently pioneering in the Indian D2C space.
Growth Opportunities
- B2B Corporate Wellness: Partnering with large IT firms to provide ‘Quit Kits’ for employees as part of health insurance perks.
- Pharmacy Retail: Expanding from D2C to offline chemist chains across India to increase accessibility.
- Subscription Models: Creating a monthly recurring revenue model for gummies and flavor core replacements.
- Global Export: Taking the ‘Flow’ device to international markets where vaping is being restricted but nicotine-free alternatives are welcomed.
Quitci: Ideal Target Audience & Demographics
| Demographic | Details |
|---|---|
| Primary Age Group | 25 – 40 Years |
| Secondary Age Group | 18 – 24 Years (Early adopters) |
| Interests | Biohacking, Fitness, Mental Health |
| Platform Preference | Instagram, LinkedIn, YouTube |
| Geography | Tier 1 & Tier 2 Cities (Mumbai, Bengaluru, Delhi) |
| Buying Behavior | Trial-based, Impulse buy via Social Ads |
Marketing and Distribution Strategy
Quitci’s marketing strategy is heavily reliant on educational content and social proof. Since quitting smoking is a deeply personal journey, the brand uses storytelling to connect with its audience. They focus on the ‘hidden costs’ of smoking—not just health, but the impact on physical appearance and social confidence. Their distribution is currently 100% digital, allowing them to maintain higher margins and collect valuable customer data for their therapy programs.
Customer Acquisition
The brand utilizes Meta Ads (Facebook and Instagram) to target users interested in health, wellness, and ‘quit smoking’ keywords. Their Customer Acquisition Cost (CAC) is kept manageable by offering a low-friction entry point—the CBT sessions—which then upsells the physical products. Influencer marketing with fitness coaches and doctors who advocate for nicotine-free living also plays a crucial role in building trust, which is the biggest barrier in this industry.
Distribution Channels
- D2C Website: The primary hub for sales and therapy session bookings.
- E-commerce Marketplaces: Presence on Amazon and Flipkart for wider reach.
- Social Commerce: Leveraging Instagram shops and WhatsApp for direct customer interaction.
- Future Roadmap: Tie-ups with specialized diagnostic labs and wellness centers.
Social Media and Content Strategy
On social media, Quitci focuses on community building. They share testimonials from ‘Quitters’ and provide daily tips on managing stress without cigarettes. Their content is designed to be supportive rather than preachy, using memes and relatable office scenarios where smoking is common. This approach helps in reducing the stigma and making the quitting process feel ‘achievable’ and ‘fun’ as mentioned in their pitch.
Quitci Shark Tank Deal Outcome
Despite the impressive ₹1.1 Crores revenue and the medical credentials of Dr. Vinod Prakash, Quitci did not secure a deal on Shark Tank India. The primary reason for the rejection was medical skepticism from Namita Thapar. She argued that the dosage of active ingredients like melatonin (1mg) was too low to be clinically effective and that the founders lacked the necessary clinical trials to prove their ‘Zero Craving’ claims. She famously stated that she felt they were “fueling the masses” with misleading promises.
| Shark | Offer Detail |
|---|---|
| Namita Thapar | Out – Questioned medical evidence and ethics |
| Anupam Mittal | Out – Concerned about the scalability of the habit replacement device |
| Vineeta Singh | Out – Not convinced by the product-market fit for gummies |
| Peyush Bansal | Out – Liked the design but stayed out due to medical ambiguity |
| Final Decision | No Deal |
Quitci Post-Show Update
Verified post-show updates for Quitci are not yet available. We will update this section as reliable information is published regarding their clinical trials or further expansion into retail pharmacies.
Business Analysis & Lessons
The Quitci pitch serves as a significant case study in the importance of clinical validation when pitching a health-tech product. While the founders had a strong ‘problem-solution’ narrative and solid sales of ₹33 Lakhs per month, their failure to provide data on bioavailability and clinical outcomes was a deal-breaker for the Sharks. In the wellness industry, especially for addiction, the line between a functional supplement and a ‘placebo’ is thin, and entrepreneurs must be armed with rigorous data to cross that line.
However, the business model itself is strategically clever. By addressing the psychological habit (oral fixation) and the chemical withdrawal separately, they have created a two-pronged attack on addiction. Their bootstrapped growth to ₹1.1 Crores in revenue shows that there is a genuine consumer appetite for non-nicotine alternatives, even if the medical community remains skeptical about the current formulation’s efficacy.
Key Takeaways
- Evidence is King: For medical founders, having an MBBS is not enough; you must present specific clinical trials for your proprietary formulation.
- Habit vs. Chemical: Successful addiction products must solve the physical ritual of the habit, not just the chemical craving.
- D2C Scalability: Scaling to ₹33 Lakhs/month without external funding proves that niche health problems can be high-growth categories.
- Transparency: Being clear about what a product can’t do is as important as what it can do to build long-term brand trust.
Pitch Conclusion
The Quitci story is a testament to the growing trend of ‘better-for-you’ health alternatives in India. While they walked away without a deal due to intense scrutiny over their medical claims, their ₹1.1 Crores revenue and clear vision for a nicotine-free future mark them as a brand to watch. If they can secure the clinical validation requested by Namita Thapar, they could potentially disrupt the entire smoking cessation category. If you enjoyed this breakdown, check out Zerodor, Perfora, and upliance.ai.
[faq_accordian]